logo
  

TransDigm Group Issues FY20 Outlook Below View- Quick Facts

While reporting its fourth-quarter financial results on Tuesday, TransDigm Group Inc. (TDG) forecast fiscal 2020 adjusted earnings in a range of $19.80 to $21.20 per share, compared with $18.27 per share in fiscal 2019.

The company also projects full-year sales in a range of $6.175 billion to $6.325 billion, compared with $5.223 billion in fiscal 2019.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $21.25 per share for the year on revenues of $6.34 billion. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT